RE: Slippery slope30 Dec 2021 16:36
I understand the pessimism FFS.
But for the sake of a happy new year weekend I am hanging my hat, and everything else on these very recent comments to shareholders by Riddell.
• The Board is confident, following recent preclinical data in NXP002 and the strengthening of its IP portfolio around NXP004, that the near-term prospects for these products are strong
• (Those prospects) will be further enhanced by additional pre-clinical development, including formulation work, toxicology studies, and preparations for Phase I trials, in addition to parallel business development work with potential partners.
• As the business strategy is executed, the Company is confident that this will be reflected by an increase in the share price, which will both increase the amount of money received by Nuformix in the Lanstead subscription, but also benefit Lanstead as the value of its investment will be higher.
This price seems slightly crazy. Can only hope the new year is a lot lot better.
Wishing you and all demoralised Nuformix shareholders a Happy New Year.
GLA